Manthan Shah, MD
Ophthalmology · Maywood, ILNPI 1851684476
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 66.9% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $5,505 and has fallen 75.5% since, to $1,347 in 2025.
Across 61 payments — averaging $133.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Onmark, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$679
- Alimera Sciences, Inc.$184
- Novartis$143
- Eyepoint US, Inc.$135
- plus $375 from 8 others
What the payments were for
- Consulting fees$4,65557%
- Travel & lodging$1,02413%
- Food & beverage$2,47330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 14 | $5,453 |
| Onmark, Inc. | 9 | $1,183 |
| Regeneron Healthcare Solutions, Inc. | 17 | $679 |
| Alimera Sciences, Inc. | 3 | $184 |
| Novartis | 2 | $143 |
| Eyepoint US, Inc. | 2 | $135 |
| Genentech USA, Inc. | 4 | $115 |
| Astellas Pharma US Inc | 3 | $64 |
| Sight Sciences, Inc. | 1 | $62 |
| Sandoz | 2 | $46 |
| Biogen | 1 | $26 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| Carl Zeiss Meditec USA, Inc. | 1 | $22 |
| Coherus Oncology, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,152 in reported general payments places this provider in the 85th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 103 | $4,410 |
| Ketorolac Tromethamine | 100 | $3,112 |
| Fluorometholone | 12 | $531 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $453 |
| Brimonidine Tartrate | 52 | $398 |
| Latanoprost | 11 | $116 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Maywood
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.